Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of arfolitixorin versus leucovorin with FOLFOX + bevacizumab in metastatic colorectal cancer
jRCT2080224951Phase 3Completed
- Sponsor
- Isofol Medical
- Start
- Nov 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of arfolitixorin in colorectal adenocarcinoma (mCRC) and metastatic colon cancer (mCRC) (2 arms), sponsored by Isofol Medical. Started Nov 2019; status: completed.
02
Drugs
arfolitixorin
03
Conditions
colorectal adenocarcinoma (mCRC)metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on jRCT2080224951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224951.